Your browser doesn't support javascript.
loading
Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
Jarius, S; Wilken, D; Haas, J; Ruprecht, K; Komorowski, L; Wildemann, B.
Affiliation
  • Jarius S; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.
  • Wilken D; Euroimmun AG, Luebeck, Germany.
  • Haas J; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Ruprecht K; Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Komorowski L; Euroimmun AG, Luebeck, Germany.
  • Wildemann B; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
J Neurol ; 268(10): 3758-3765, 2021 Oct.
Article in En | MEDLINE | ID: mdl-33770235
ABSTRACT

BACKGROUND:

A positive MRZ reaction, as defined by intrathecal IgG production against at least two of its constituents, measles virus (M), rubella virus (R) and varicella zoster virus (Z), is detectable in ~ 63% of patients with multiple sclerosis (MS) and is currently considered the laboratory marker with the highest specificity and positive likelihood ratio for MS. However, M, R and Z are only the most well-established constituents of a broader intrathecal humoral immune response in MS.

OBJECTIVE:

To identify additional anti-microbial antibodies inclusion of which in the classical MRZ panel may result in increased sensitivity without compromising the marker's high specificity for MS.

METHODS:

We determined the antibody indices (AIs) for 11 viral and bacterial agents (M, R, Z, herpes simplex virus, Epstein-Barr virus, mumps virus, cytomegalovirus, parvovirus B19, Bordetella pertussis, Corynebacterium diphtheriae, and Clostridium tetani) in paired cerebrospinal fluid and serum samples from patients with MS and disease controls.

RESULTS:

A positive 'classical' MRZ reaction was found in 17/26 (65.4%) MS patients. The five most frequently positive AIs among patients with MS were M (76.9%), Z (61.5%), R (57.7%), parvovirus B19 (42.3%), and mumps (28%). Addition of parvovirus B19 and mumps virus to the MRZ panel resulted in an increase in sensitivity in the MS group from 65.4% to 73.1%, with 22% of the initially MRZ-negative patients exhibiting a de novo-positive response. The extended MRZ panel ('MRZplus') distinguished sharply between MS (≥ 3 AIs in 90% of all positives) and controls (varying diagnoses, from migraine to vasculitis; 0-1 AIs; p < 0.000001). The highest median AI in the MS group was found for parvovirus B19 (3.97), followed by measles virus (2.79).

CONCLUSION:

Inclusion of parvovirus B19 and mumps virus in the test panel resulted in an increase in the sensitivity and discriminatory power of MRZ. Our results provide a strong rational for prospective studies investigating the role of extended MRZ panels in the differential diagnosis of MS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parvovirus B19, Human / Epstein-Barr Virus Infections / Multiple Sclerosis Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: J Neurol Year: 2021 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parvovirus B19, Human / Epstein-Barr Virus Infections / Multiple Sclerosis Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: J Neurol Year: 2021 Document type: Article Affiliation country: Germany